Hikma Pharmaceuticals Plc (HKMPF) Given Average Rating of “Hold” by Brokerages
Shares of Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) have received an average recommendation of “Hold” from the seven analysts that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company.
Separately, Zacks Investment Research cut shares of Hikma Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 10th.
Hikma Pharmaceuticals (OTCMKTS:HKMPF) opened at $14.00 on Friday. Hikma Pharmaceuticals has a 1-year low of $12.40 and a 1-year high of $27.50.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.